NCT06148636 is a EARLY_PHASE1 clinical trial of [212Pb] VMT-α-NET in Neuroendocrine Tumors, sponsored by David Bushnell.

Who is sponsoring NCT06148636?

NCT06148636 is sponsored by David Bushnell.

What drugs are being tested in NCT06148636?

Interventions in NCT06148636: [212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT.

What condition does NCT06148636 study?

NCT06148636 studies Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas.

Is NCT06148636 still recruiting?

NCT06148636 is currently active, enrolled. Last updated 4 November 2025.

Last reviewed 2025-11-04 · How we verify

NCT06148636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Active, enrolled EARLY_PHASE1 Last updated 4 November 2025

What this trial tests

EARLY_PHASE1 trial testing [212Pb] VMT-α-NET in Neuroendocrine Tumors in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

10 November 2023

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	David Bushnell
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	10 November 2023
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

[212Pb] VMT-α-NET — full drug profile →
[203Pb] VMT-α-NET SPECT/CT

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Neuroendocrine Tumor of the Lung — all drugs for Neuroendocrine Tumor of the Lung →
Neuroendocrine Tumor Grade 1 — all drugs for Neuroendocrine Tumor Grade 1 →
Neuroendocrine Tumor Grade 2 — all drugs for Neuroendocrine Tumor Grade 2 →

Sponsor

David Bushnell — full company profile →

Who can join

Adults 18 to 80, any sex, with Neuroendocrine Tumors or Neuroendocrine Tumor of the Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

New Approaches in Radiotherapy.
Webster M, Podgorsak A, Li F, Zhou Y, et al · · 2025 · cited 9× · PMID 40563630 · DOI 10.3390/cancers17121980
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.
Grewal US, Gbolahan OB, Takalkar AM, Halperin DM. · · 2025 · cited 3× · PMID 40162745 · DOI 10.1080/14796694.2025.2485650
Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Berckmans Y, Kleynhans J, Van Mechelen S, Goffin K, et al · · 2026 · cited 1× · PMID 41510167 · DOI 10.7150/thno.126086
A Phase 0 Imaging Trial of [<sup>203</sup>Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [<sup>212</sup>Pb]Pb-VMT-α-NET.
Graves SA, Bushnell DL, Schultz MK, Jain S, et al · · 2026 · PMID 41644295 · DOI 10.2967/jnumed.125.270083
Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors.
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, et al · · 2025 · PMID 41304857 · DOI 10.3390/ph18111608
Options and Considerations in the Management of Peritoneal Disease in Patients with Small Bowel Neuroendocrine Tumors.
Chang J, Grewal US, Sherman SK, Howe JR. · · 2025 · PMID 41082053 · DOI 10.1007/s11864-025-01364-y
The University of Iowa Neuroendocrine Tumor Clinic.
Howe JR, Menda Y, Chandrasekharan C, Bellizzi AM, et al · · 2025 · PMID 39349242 · DOI 10.1016/j.eprac.2024.09.018

Verify or expand the search:

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other David Bushnell trials

Trials by the same sponsor.

NCT04614766 — A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06148636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Bushnell
Last refreshed: 4 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06148636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing